Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739815 | 0.93 | MAPK11 (0.34) | MAPK11MAPK14 | |
| SCHEMBL6742079 | 0.82 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6745850 | 0.78 | PTGER3 (0.37) | SLC6A2SLC6A4SLC6A3REN | |
| SCHEMBL6782259 | 0.72 | QDPR (0.48) | MAPK11MAPK14SLC6A4HTR1D | |
| SCHEMBL6742204 | 0.72 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5333427 | 0.70 | TAAR1 (0.32) | — | |
| SCHEMBL8775410 | 0.70 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13727500 | 0.69 | HTT (0.48) | — | |
| SCHEMBL17448338 | 0.69 | PDE1C (0.43) | — | |
| SCHEMBL15344914 | 0.69 | PDE1C (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | claimed |
| EP-1196380-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2002-04-17 | — | — | EP | claimed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | claimed |
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
| EP-1196380-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | MAPK11 4146/4885MAPK14 4518/4885SLC6A2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.